FIRST REAL-WORLD STUDY ASSESSING HEALTH UTILITY VALUES FOR CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA USING THE EQ-5D

Author(s)

McBride D1, Chambenoit O2, Chiva-Razavi S2, Lynde C3, Sussman G4, Chapman-Rothe N5, Weller K6, Maurer M6, Koenders J7, Knulst AC8, Elberink JN9, Halliday A10, Alexopoulos ST10, Nakonechna A11, Abouzakouk M11, Sweeney C12, Radder C12, Wolin D13, Hollis K12, Tian H14, Balp M15, Grattan C16
1RTI Health Solutions, Manchester, UK, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Lynderm Research Inc., Toronto, ON, Canada, 4St Michael's Hospital, University of Toronto, Toronto, ON, Canada, 5Novartis Pharma GmbH, Nuernberg, Germany, 6Charite - Universitätsmedizin Berlin, Berlin, Germany, 7Novartis Pharma B.V., Arnhem, The Netherlands, 8University Medical Center Utrecht, Utrecht, The Netherlands, 9Unviersity Medical Center Groningen, Groningen, The Netherlands, 10Novartis Pharmaceuticals UK Limited, Surrey, UK, 11Hull and East Yorkshire NHS Hospital Trust, Hull, UK, 12RTI Health Solutions, Research Triangle Park, NC, USA, 13RTI Health Solutions, Ann Arbor, MI, USA, 14Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 15Novartis Pharma AG, Basel, Switzerland, 16Norfolk and Norwich University Hospital, Norwich, UK

OBJECTIVES: Although chronic spontaneous (idiopathic) urticaria (CSU/CIU) is not life threatening, it can significantly impact a patient’s life when not adequately controlled by medication. Patients experience disturbing itch, intermittent pain, lack of sleep, occupational disabilities and social isolation with high impact on health-related quality of life (HRQoL). However, data on the humanistic burden associated with symptomatic persistent CSU/CIU is scarce. Here we present data on utility values from the first international burden of illness study in CSU/CIU. METHODS: ASSURE-CSU is an observational, non-interventional study which included a 1-year retrospective medical record abstraction and a cross-sectional patient-reported outcomes survey. Adult CSU/CIU patients aged >18 years with disease persisting for ≥12 months despite treatment were assessed. Utility values and domain scores from EQ-5D-3L were described for Canada, Germany, UK and the Netherlands. RESULTS: A total of 88, 98, 79 and 99 patients completed the patient survey which included the EQ-5D-3L in Canada, Germany, UK and the Netherlands, respectively. The mean (SD) EQ-5D-3L utility score was 0.71 (0.30) for Canada; 0.71 (0.25) for Germany; 0.72 (0.31) for UK and 0.76 (0.27) for the Netherlands. Among the different dimensions of EQ-5D-3L, pain/discomfort was the most affected with 62.0%, 70.5%, 61.5% and 56.6% of patients reporting moderate to extreme problems, respectively. The second most affected dimension was anxiety/depression for Canada, Germany and UK with 41.8%, 51.6% and 45.6% of patients reporting moderate to extreme problems, respectively. For the Netherlands, usual activities (44.4%) was the second most affected dimension. Impact across all dimensions increased with disease severity and correspondingly utility values decreased. CONCLUSIONS: This is the first real-world study to assess utility values in CSU/CIU using EQ-5D. Utility scores were similar among the countries and ranged from 0.71 to 0.76, suggesting that CSU/CIU have significant impact on the patients’ health status. Pain/discomfort was the most affected dimension across countries.

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PSS54

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities

Disease

Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×